Pyratine XR offers long term benefits

Written by on July 23, 2010 in research with 1 Comment

Always quick to generate a press release, Pyratine XR has been seen some recently published research, this time on the long term efficacy when treating mild to moderate rosacea.

This latest research is in addition to the May 2009 JDD article, Topical PRK 124 (0.125%) lotion for improving the signs and symptoms of rosacea, and the 2007 Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea

So now we have the June 2010 Journal of Drugs in Dermatology article; Long-term Efficacy and Safety of Topical PRK-124 (0.125%) Lotion (PyratineXR™) in the Treatment of Mild-to-Moderate Rosacea.

Although this study only included 14 patients, it did last 48 weeks which seems to be much longer than the usual period for a study of this type. It is potentially good news that Pyratine XR offers sustained benefit over the long term.

At worst the product didn’t seem to induce an irritation and at best offers a measurable benefit for the redness and papules and pustules of rosacea.

Pyratine XR continues to attract only modest attention in the online rosacea forums. For some snippets of user feedback see Pyratine XR user reviews.

Long-term Efficacy and Safety of Topical PRK 124 (0.125%) Lotion (Pyratine-XR) in the Treatment of Mild-to-Moderate Rosacea

J Drugs Dermatol. 2010 June;9(6):647.

Background: Many patients with rosacea cannot tolerate extended treatment periods with topical agents because their skin sensitivity is often increased.

Objective: To determine the long-term efficacy and tolerability of a new moisturizing lotion for improving the signs and symptoms of mild-to-moderate rosacea.

Methods: In a 48-week, open-label study, a moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK-124 (0.125%, Pyratine-XR™, Senetek PLC, Napa, CA) was applied twice daily by 18 subjects with mild-to-moderate rosacea. Clinical improvements were assessed by the treating physician. Skin barrier function was measured by transepidermal water loss after treatment. Tolerability and cosmetic outcome were evaluated by subjects.

Results: Subjects experienced a mean 44 percent reduction in erythema severity and a mean 89 percent reduction in inflammatory lesion count at week 48. Reductions were significant (P≤0.05) in both erythema and lesions at weeks 24, 36 and 48. Statistically significant (P≤0.05) improvements in telangiectasias, transepidermal water loss and dryness were noted. Overall clinical improvement was observed in 81 percent of subjects and the investigator’s global assessment steadily improved throughout the study. Treatments were well-tolerated and cosmetically acceptable. Treatment-induced skin irritation was not observed.

Conclusion: The new moisturizing lotion containing furfuryl tetrahydropyranyladenine as PRK 124 is efficacious, does not irritate skin, and is well tolerated for at least 48 weeks.

Featured Product

Related Articles

Read more about: research

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. maryam says:

    i had rosacea for 5 years. i tried everything like most people here are doing. i went to a 5th ave doctor to holistic to a holistic school trying to solve this issue. nothing helped till i got my blood tested form deficiencies. i was extremly low in vitamin D. i started taking 10,000 iu’s of vitamin d daily and within 3 weeks i started seeing results and within 6 weeks i cleared up completely! vitamin d dificiency is a new discovery and leads to many health issues and hormonal imbalance. stop using sun block and take your vitamin d. i promiss you, you will be saved!

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.